REVENUE (Tables)

6 Months Ended

Apr. 30, 2021

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:


	Three Months Ended April 30,
	2021								2020
	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total		Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Revenue by Region
Americas	$	231	$	187	$	163	$	581	$	170	$	161	$	126	$	457
Europe	155		154		106		415		111		131		92		334
Asia Pacific	288		195		46		529		245		157		45		447
Total	$	674	$	536	$	315	$	1,525	$	526	$	449	$	263	$	1,238



	Six Months Ended April 30,
	2021								2020
	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total		Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Revenue by Region
Americas	$	455	$	366	$	315	$	1,136	$	379	$	328	$	244	$	951
Europe	345		301		206		852		278		264		184		726
Asia Pacific	596		401		88		1,085		507		327		84		918
Total	$	1,396	$	1,068	$	609	$	3,073	$	1,164	$	919	$	512	$	2,595

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


	Three Months Ended				Six Months Ended
	April 30,				April 30,
	2021		2020		2021		2020
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical	$	531	$	400	$	1,052	$	823
Chemical and Energy	314		267		642		579
Diagnostics and Clinical	233		200		449		394
Food	144		114		306		244
Academia and Government	143		115		285		256
Environmental and Forensics	160		142		339		299
Total	$	1,525	$	1,238	$	3,073	$	2,595

Revenue by Type
Instrumentation	$	632	$	491	$	1,313	$	1,084
Non-instrumentation and other	893		747		1,760		1,511
Total	$	1,525	$	1,238	$	3,073	$	2,595

Contract Liabilities and Changes in Balances

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2021:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2020	$	446
Net revenue deferred in the period	304
Revenue recognized that was included in the contract liability balance at the beginning of the period	(267)
Change in deferrals from customer cash advances, net of revenue recognized	7

Currency translation and other adjustments	7
Ending balance as of April 30, 2021	$	497